Badrul Chowdhury
      OUR PEOPLE

      Dr. Badrul Chowdhury

      MD (Doctor of Medicine). PhD in Immunology

      Сhief Life Sciences Officer, Smoke-Free Products

      Contact

      Badrul became Chief Life Sciences Officer, Smoke-Free Products, in September 2022. He leads a talented team of scientific experts overseeing best-in-class programs to demonstrate the individual, clinical, and public health benefits of PMI’s smoke-free products for adult smokers who would otherwise continue to smoke.   

      Badrul joined PMI from a U.S.-based biotech company developing inhalation products for rare respiratory diseases, where he was Chief Medical Officer. Prior to that, he was AstraZeneca’s Senior Vice President and Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late-Stage Development in Biopharmaceuticals R&D.

      Before joining the pharmaceutical industry, Badrul served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration for almost 21 years, from 1997 to 2018, providing scientific and regulatory oversight of therapies for lung, autoimmune, and inflammatory diseases. He is a medical doctor and holds a PhD in immunology from Memorial University of Newfoundland, Canada.

      Read this letter from our Chief Life Sciences Officer as he welcomes our readers to learn more about PMI's science.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.